| |
Serum 25(OH)D
|
---|
| |
Continuous
|
Categorical
| |
---|
| |
per 10 nmol/L decrement
|
< 35 nmol/L
|
35-55 nmol/L
|
≥ 55 nmol/L
| |
---|
Variable
|
Total no.
|
HR
|
95%CI
|
P
trend
b
|
HR
|
95%CI
|
HR
|
95%CI
| |
P
interaction
c
|
---|
BMI, kg/m2d
| | | | | | | | | |
0.74
|
< 26
|
382
|
1.05
|
0.66 to 1.44
|
0.81
|
0.64
|
0.08 to 5.00
|
0.02
|
0.00 to 2.06
|
Referent
| |
≥ 26
|
393
|
1.15
|
0.94 to 1.36
|
0.20
|
2.57
|
0.88 to 7.54
|
0.60
|
0.19 to 1.92
|
Referent
| |
Leisure time physical activity, MET-h/wk
| | | | | | | | | |
0.49
|
< 37
|
631
|
1.04
|
0.92 to 1.17
|
0.50
|
1.19
|
0.62 to 2.29
|
0.63
|
0.30 to 1.32
|
Referent
| |
≥ 37
|
629
|
1.19
|
1.03 to 1.35
|
0.03
|
1.90
|
0.85 to 4.24
|
0.57
|
0.22 to 1.48
|
Referent
| |
HRT use
| | | | | | | | | |
0.40
|
Never, past
|
746
|
1.13
|
1.01 to 1.25
|
0.04
|
1.89
|
1.09 to 3.26
|
0.61
|
0.31 to 1.19
|
Referent
| |
Current
|
506
|
1.03
|
0.86 to 1.21
|
0.73
|
0.89
|
0.26 to 3.05
|
1.17
|
0.46 to 2.98
|
Referent
| |
ER status
| | | | | | | | | |
0.78
|
ER+
|
903
|
1.08
|
0.97 to 1.19
|
0.17
|
1.70
|
0.95 to 3.05
|
0.72
|
0.39 to 1.35
|
Referent
| |
ER-
|
276
|
1.09
|
0.84 to 1.35
|
0.50
|
1.48
|
0.38 to 5.76
|
0.81
|
0.21 to 3.09
|
Referent
| |
- 25(OH)D, 25-hydroxyvitamin D; BMI, body mass index; CI, confidence interval; ER, estrogen receptor; HR, hazard ratio; HRT, hormone replacement therapy.
- a Stratified by age at diagnosis and season, adjusted for tumor size, nodal status, metastases, tumor grade, estrogen/progesterone receptor status, diabetes, mode of detection.
- b Calculated by using serum 25(OH)D as a continuous variable.
- c Calculated by entering in the model the cross-product of 25(OH)D as a continuous variable with the covariate as a binary variable. Cutpoints for BMI and leisure time physical activity were based on median values.
- d Participants with blood collection after start of chemotherapy and with BMI obtained more than one month before/after blood collection were excluded from this analysis stratified by BMI.